Dietary omega-3 fatty acids modulate the eicosanoid profi le in man primarily via the CYP-epoxygenase pathway

Journal of Lipid Research

Volumn 55, Issue 6, 2014, Pages 1150-1164

  Fischer, Robert ^a,b   Konkel, Anne ^a   Mehling, Heidrun ^b   Blossey, Katrin ^a   Gapelyuk, Andrej ^c   Wessel, Niels ^c   Von Schacky, Clemens ^d   Dechend, Ralf ^b,e   Muller, Dominik N ^b   Rothe, Michael ^f   Luft, Friedrich C ^b   Weylandt, Karsten ^b   Schunck, Wolf Hagen ^a  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b Experimental and Clinical Research Center ECRC   (Germany)

^c HUMBOLDT UNIVERSITY   (Germany)

^d Omegametrix GmbH   (Germany)

^e HELIOS KLINIKUM BERLIN BUCH   (Germany)

^f LIPIDOMIX GMBH   (Germany)

Author keywords

Cytochrome P450; Lipidomics; Nutrition

Indexed keywords

ARACHIDONIC ACID; CYTOCHROME P450; DOCOSAHEXAENOIC ACID; ICOSANOID; ICOSAPENTAENOIC ACID; LEUKOTRIENE; LIPOXYGENASE; NATURAL PRODUCT; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PROSTACYCLIN; PROSTAGLANDIN E; PROSTAGLANDIN SYNTHASE; RESOLVIN D; RESOLVIN E; THROMBOXANE; UNCLASSIFIED DRUG; ARACHIDIC ACID;

ADULT; ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; ERYTHROCYTE; FAT INTAKE; FEMALE; HUMAN; HUMAN EXPERIMENT; LIPID COMPOSITION; MALE; METABOLITE; NORMAL HUMAN; PRIORITY JOURNAL; URINE LEVEL; ADOLESCENT; BLOOD; CLINICAL TRIAL; DIETARY SUPPLEMENT; METABOLISM; MIDDLE AGED;

ADOLESCENT; ADULT; CYTOCHROME P-450 ENZYME SYSTEM; DIETARY SUPPLEMENTS; EICOSANOIC ACIDS; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 84901682040     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M047357     Document Type: Article

References (82)

1. Konkel, A., and W. H. Schunck. 2011. Role of cytochrome P450 enzymes in the bioactivation of polyunsaturated fatty acids. Biochim. Biophys. Acta. 1814: 210-222.
2. Capdevila, J. H., and J. R. Falck. 2002. Biochemical and molec ular properties of the cytochrome P450 arachidonic acid monooxygenases. Prostaglandins Other Lipid Mediat. 68,69: 325-344.
3. Funk, C. D. 2001. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science. 294: 1871-1875.
4. Buczynski M.W.,D.S. Dumlao,E.A. Dennis, 2009. Proteomics. An integrated omics analysis of eicosanoid biology. J. Lipid Res., 50, 1015-1038.
5. Kroetz, D. L., and D. C. Zeldin. 2002. Cytochrome P450 pathways of arachidonic acid metabolism. Curr. Opin. Lipidol. 13: 273-283.
6. Campbell, W. B., and I. Fleming. 2010. Epoxyeic osatrienoic acids and endothelium-dependent responses. Pfl ugers Arch. 459: 881-895.
7. McGiff, J. C., and J. Quilley. 1999. 20-HETE and the kidney: resolution of old problems and new beginnings. Am. J. Physiol. 277: R607-R623.
8. Roman, R. J. 2002. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol. Rev. 82: 131-185.
9. Spector, A. A., and A. W. Norris. 2007. Action of epoxyeicosatrienoic acids on cellular function. Am. J. Physiol. Cell Physiol. 292: C996-C1012.
10. Harris, T. R., and B. D. Hammock. 2013. Soluble epoxide hydrolase: gene structure, expression and deletion. Gene. 526: 61-74.
11. Wu, C. C., T. Gupta, V. Garcia, Y. Ding, and M. L. Schwartzman. 2014. 20-HETE and blood pressure regulation: clinical implications. Cardiol Rev. 22: 1-12.
12. Seubert, J. M., D. C. Zeldin, K. Nithipatikom, and G. J. Gross. 2007. Role of epoxyeicosatrienoic acids in protecting the myocardium following ischemia/reperfusion injury. Prostaglandins Other Lipid Mediat. 82: 50-59.
13. Hoff, U., I. Lukitsch, L. Chaykovska, M. Ladwig , C. Arnold, V. L. Manthati, T. F. Fuller, W. Schneider, M. Gollasch, D. N. Muller, et al. 2011. Inhibition of 20-HETE synthesis and action protects the kidney from ischemia/reperfusion injury. Kidney Int. 79: 57-65.
14. Regner, K. R., A. Zuk, S. K. Van Why, B. D. Shames, R. P. Ryan, J. R. Falck, V. L. Manthati, M. E. McMullen, S. R. Ledbetter, and R. J. Roman. 2009. Protective effect of 20-HETE analogues in experimental renal ischemia reperfusion injury. Kidney Int. 75: 511-517.
15. Imig, J. D., A. N. Simpkins, M. Renic, and D. R. Harder. 2011. Cytochrome P450 eicosanoids and cerebral vascular function. Expert Rev. Mol. Med. 13: e7.
16. Deng, Y., K. N. Theken, and C. R. Lee. 2010. Cytochrome P450 epoxygenases, soluble epoxide hydrolase, and the regulation of cardiovascular infl ammation. J. Mol. Cell. Cardiol. 48: 331-341.
17. Imig, J. D., and B. D. Hammock. 2009. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat. Rev. Drug Discov. 8: 794-805.
18. Lauterbach, B., E. Barbosa-Sicard, M. H. Wang, H. Honeck, E. Kargel, J. Theuer, M. L. Schwartzman, H. Haller, F. C. Luft, M. Gollasch, et al. 2002. Cytochrome P450-dependent eicosapentaen oic acid metabolites are novel BK channel activators. Hypertension. 39: 609-613.
19. Barbosa-Sicard, E., M. Markovic, H. Honeck, B. Christ, D. N. Muller, and W. H. Schunck. 2005. Eicosape ntaenoic acid metabolism by cytochrome P450 enzymes of the CYP2C subfamily. Biochem. Biophys. Res. Commun. 329: 1275-1281.
20. Fer, M., Y. Dreano, D. Lucas, L. Corcos, J. P. Salaun, F. Berthou, and Y. Amet. 2008. Metabolism of eicosapentaenoic and docosahexaenoic acids by recombinant human cytochromes P450. Arch. Biochem. Biophys. 471: 116-125.
21. Fer, M., L. Cor cos, Y. Dreano, E. Plee-Gautier, J. P. Salaun, F. Berthou, and Y. Amet. 2008. Cytochromes P450 from family 4 are the main omega hydroxylating enzymes in humans: CYP4F3B is the prominent player in PUFA metabolism. J. Lipid Res. 49: 2379-2389.
22. Arnold, C., M. Markovic, K. Blossey, G. Wallukat, R. Fischer, R. Dechend, A. Konkel, C. von Schacky, F. C. Luft, D. N. Muller, et al. 2010. Arachidonic acid-metabolizing cytochrome P450 enzymes are targets of omega-3 fatty acids. J. Biol. Chem. 285: 32720-32733.
23. Morisseau, C., B. Inceoglu, K. Schmelzer, H. J. Tsai, S. L. Jinks, C. M. Hegedus, and B. D. Ham mock. 2010. Naturally occurring monoepoxides of eicosapentaenoic acid and docosahexaenoic acid are bioactive antihyperalgesic lipids. J. Lipid Res. 51: 3481-3490.
24. Westphal, C., A. Konkel, and W. H. S chunck. 2011. CYPeicosanoids- A new link between omega-3 fatty acids and cardiac disease Prostaglandins Other Lipid Mediat. 96: 99-108.
25. Ye D..D. Zhang,C. Oltman,K. Dellsperger,H. C. Lee,M. VanRollins, 2002, Cytochrome p-450 epoxygenase metabolites of docosahexaenoate potently dilate coronary arterioles by activating large-conductance calcium-activated potassium channels. J. Pharmacol. Exp. Ther.,303,768-776.
26. Node, K., Y. Huo, X. Ruan, B. Yang, M. Spiecker, K. Ley, D. C. Zeldin, and J. K. Liao. 1999. Anti-infl ammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science. 285: 1276-1279.
27. Morin, C., M. Sirois, V. Echave, R. Albadine, and E. Rousseau. 2010. 17,18-epoxyeicosatetraenoic acid targets PPAR and p38 mitogenactivated protein kinase to mediate its anti-infl ammatory ef fects in the lung: role of soluble epoxide hydrolase. Am. J. Respir. Cell Mol. Biol. 43: 564-575.
28. Panigrahy, D., M. L. Edin, C. R. Lee, S. Huang, D. R. Bielenberg, C. E. Butterfi eld, C. M. B arnes, A. Mammoto, T. Mammoto, A. Luria, et al. 2012. Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice. J. Clin. Invest. 122: 178-191.
29. Zhang, G., D. Panigrahy, L. M. Mahakian, J. Yang, J. Y. Liu, K. S. Stephen Lee, H. I. Wettersten, A. Ulu, X. Hu, S. Tam, et al. 2013. Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis. Proc. Natl. Acad. Sci. U SA. 110: 6530-6535.
30. Kris-Etherton, P. M., W. S. Harris, and L. J. Appel. 2002. Fish consumption, fi sh oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 106: 2747-2757.
31. Lavie, C. J., R. V. Milani, M. R. Mehra, and H. O. Ventura. 2009. Omega-3 polyunsaturated fatty acids and cardiovascular diseases. J. Am. Coll. Cardiol. 54: 585-594.
32. Harris , W. S., and C. Von Schacky. 2004. The Omega-3 Index: a new risk factor for death from coronary heart disease Prev. Med. 39: 212-220.
33. Gomolka, B., E. Siegert, K. Blossey, W. H. Schunck, M. Rothe, and K. H. Weylandt. 2011. Analysis of omega-3 and omega-6 fatty acidderived lipid metabolite formation in human and mouse blood samples. Prostaglandins Other Lipid Mediat. 94: 81-87.
34. Mozaff arian, D. 2008. Fish and n-3 fatty acids for the prevention of fatal coronary heart disease and sudden cardiac death. Am. J. Clin. Nutr. 87: 1991S-1996S.
35. Simopoulos, A. P. 2008. The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. Exp. Biol. Med. (Maywood). 233: 674-688.
36. Leaf, A., J. X. Kang, Y. F. Xiao, and G. E. Billman. 2003. Clinical prevention of sudden cardiac death by n-3 polyunsaturated fatty acids and mechanism of prevention of arrhythmias by n-3 fi sh oils. Circulation. 107: 2646-2652.
37. De Caterina, R. 2011. n-3 fatty acids in cardiovascular disease. N. Engl. J. Med. 364: 2439-2450.
38. Hooper, L., R. L. Thompson, R. A. Harrison, C. D. Summerbell, A. R. Ness, H. J. Moore, H. V. Worthington, P. N. Durrington, J. P. Higgin s, N. E. Capps, et al. 2006. Risks and benefi ts of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review. BMJ. 332: 752-760.
39. Rizos, E. C., E. E. Ntzani, E. Bi ka, M. S. Kostapanos, and M. S. Elisaf. 2012. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA. 308: 1024-1033.
40. Marchioli, R., F. Barzi, E. Bomba, C. Chieffo, D. Di Gregorio, R. Di Mascio, M. G. Franzosi, E. Geraci, G. Levantesi, A. P. Maggioni, et al. 2002. Early protection against sudden death by n-3 pol yunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell Infarto Miocardico (GISSI)-Prevenzione. Circulation. 105: 1897-1903.
41. Harris, W. S., S. A. Sands, S. L. Windsor, H. A. Ali, T. L. Stevens, A. Magalski, C. B. Porter, and A. M. Borkon. 2004. Omega-3 fatty acids in cardiac biopsies from heart transplantation patients: correlation w ith erythrocytes and response to supplementation. Circulation. 110: 1645-1649.
42. Katan, M. B., J. P. Deslypere, A. P. van Birgelen, M. Penders, and M. Zegwaard. 1997. Kinetics of the incorporation of dietary fatty acids into serum cholesteryl esters, erythrocyte membranes, and adipose tissue: an 18-month controlled study. J. Lipid Res. 38: 2012-2022.
43. Arterburn, L. M., E. B. Hall, and H. Oken. 2006. Distribution, interconversion, and dose response of n-3 fatty acids in humans. Am. J. Clin. Nutr. 83: 1467S-1476S.
44. Keenan, A. H., T. L. Pedersen, K. Fillaus, M. K. Larson, G. C. Shearer, and J. W. Newman. 2012. Basal omega-3 fatty acid status affects fatty acid and oxylipin responses to high-dose n3-HUFA in healthy volunteers. J. Lipid Res. 53: 1662-1669.
45. von Schacky, C. 2009. Cardiovascular disease prevention and treatment. Prostaglandins Leukot. Essent. Fatty Acids. 81: 193-198.
46. Shearer, G. C., W. S. Harris, T. L. Pedersen, and J. W. Newman. 2010. Detection of omega-3 oxylipins in human plasma and response to treatment with omega-3 acid ethyl esters. J. Lipid Res. 51: 2074-2081.
47. Lundströ m, S. L., J. Yang, J. D. Brannan, J. Z. Haeggström, B. D. Hammock, P. Nair, P. OByrne, S. E. Dahlén, and C. E. Wheelock. 2013. Lipid mediator serum profi les in asthmatics signifi cantly shift following dietary supplementation with omega-3 fatty acids. Mol. Nutr. Food Res. 57: 1378-1389.
48. Schuchardt, J. P., S. Schmidt, G. Kressel, H. Dong, I. Willenberg, B. D. Hammock, A. Hahn, and N. H. Schebb. 2013. Comparison of free serum oxylip in concentrations in hyper-vs. normolipidemic men. Prostaglandins Leukot. Essent. Fatty Acids. 89: 19-29.
49. Karara, A., S. Wei, D. Spady, L. Swift, J. H. Capdevila, and J. R. Falck. 1992. Arachidonic acid epoxygenase: structural characterization and quantifi cation of epoxyeicosatrienoates in plasma. Biochem. Biophys. Res. Commun. 182: 1320-1325.
50. Shearer, G. C., and J. W. Newman. 2008. Lipoprotein lipase releases esterifi ed oxylipins from very low-density lipoproteins. Prostaglandins Leukot. Essent. Fatty Acids. 79: 215-222.
51. Weylandt, K. H., C. Y. Chiu, B. Gomolka, S. F. Waechter, and B. Wiedenmann. 2012. Omega-3 fatty acids and their lipid mediators: towards an understanding of resolvin and protectin formation. Prostaglandins Other Lipid Mediat. 97: 73-82.
52. Ser han, C. N., N. Chiang, and T. E. Van Dyke. 2008. Resolving infl ammation: dual anti-infl ammatory and pro-resolution lipid mediators. Nat. Rev. Immunol. 8: 349-361.
53. Serhan, C. N., R. Yang, K. Martinod, K. Kasuga, P. S. Pillai, T. F. Porter, S. F. Oh, and M. Spite. 2009. Maresins: novel macrophage mediators with potent antiinfl ammatory and proresolving actions. J. Exp. Med. 206: 15-23.
54. Dyerberg, J., H. O. Bang, E. Stoffersen, S. Moncada, and J. R. Vane. 1978. Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis Lancet. 2: 117-119.
55. Lands, W. E . 2005. Dietary fat and health: the evidence and the politics of prevention: careful use of dietary fats can improve life and prevent disease. Ann. N. Y. Acad. Sci. 1055: 179-192.
56. Terano, T., J. A. Salmon , and S. Moncada. 1984. Biosynthesis and biological activity of leukotriene B5. Prostaglandins. 27: 217-232.
57. Fischer, S., P. C. Weber, and J. Dyerberg. 1986. The prostacyclin/ thromboxane balance is favourably shifted in Greenland Eskimos. Prostaglandins. 32: 235-241.
58. von Schacky, C., S. Fischer, and P. C. Weber. 1985. Long-term effects of dietary marine omega-3 fatty acids upon p lasma and cellular lipids, platelet function, and eicosanoid formation in humans. J. Clin. Invest. 76: 1626-1631.
59. Ohnishi, H., and Y. Saito. 2013. Eicosapentaenoic acid (EPA) reduces cardiovascular events: relationship with the EPA/arachidonic acid ratio. J. Atheroscler. Thromb. 20: 861-877.
60. Wada, M., C. J. DeLong, Y. H. Hong, C. J. Rieke, I. Song, R. S. Sidhu, C. Yuan, M. Warnock, A. H. Sc hmaier, C. Yokoyama, et al. 2007. Enzymes and receptors of prostaglandin pathways with arachidonic acid-derived versus eicosapentaenoic acid-derived substrates and products. J. Biol. Chem. 282: 22254-22266.
61. Lefi ls-Lacourtablaise, J., M. Socorro, A. Geloen, P. Daira, C. Debard, E. Loizon, M. Guichardant, Z. Dominguez, H. Vidal, M. Lagarde, et al. 2013. The eicosapentaenoic acid metabolite 15-deoxy-(12,14)-prostaglandin J3 increases adipon ectin secretion by adipocytes partly via a PPAR-dependent mechanism. PLoS ONE. 8: e63997.
62. Kuklev, D. V., J. A. Hankin, C. L. Uhlson, Y. H. Hong, R. C. Murphy, and W. L. Smith. 2013. Major urinary metabolites of 6-ketoprostaglandin F2 in mice. J. Lipid Res. 54: 1906 -1914.
63. Nielsen, M. S., A. Gammelmark, T. Madsen, T. Obel, I. Aardestrup, and E. B. Schmidt. 2012. The effect of low-dose marine n-3 fatty acids on the biosynthesis of pro-infl ammatory 5-lipoxygenase pathway metabolites in overweight subjects: a randomized controlled trial. Prostaglandins Leukot. Essent. Fatty Acids . 87: 43-48.
64. Morris, M. C., F. Sacks, and B. Rosner. 1993. Does fi sh oil lower blood pressure A meta-analysis of controlled trials. Circulation. 88: 523-533.
65. Bays, H. E., A. P. Tighe, R. Sadovsky, and M. H. Davidson. 2008. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Expert Rev. Cardiovasc. Ther. 6: 391-409.
66. Mozaffarian, D., and J. H. Wu. 2011. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J. Am. Coll. Cardiol. 58: 2047-2067.
67. Cabo, J., R. Alonso, and P. Mata. 2012. Omega-3 fatty acids and blood pressure. Br. J. Nutr. 107 ( Suppl 2 ): S195-S200.
68. Davidson M. H,2006, Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. Am. J. Cardiol., 98: 27i-33i.
69. Hoshi, T., B. Wissuwa, Y. Tian, N. Tajima, R. Xu, M. Bauer, S. H. Heinemann, and S. Hou. 2013. Omega-3 fatty a cids lower blood pressure by directly activating large-conductance Ca 2+-dependent K + channels. Proc. Natl. Acad. Sci. USA. 110: 4816-4821.
70. Campbell, W. B., and J. R. Falck. 2007. Arachidonic acid metabo lites as endothelium-derived hyperpolarizing factors. Hypertension. 49: 590-596.
71. Zhang, Y., C. L. Oltman, T. Lu, H. C. Lee, K. C. Dellsperger, and M. VanRollins. 2001. EET homologs potentl y dilate coronary microvessels and activate BK(Ca) channels. Am. J. Physiol. Heart Circ. Physiol. 280: H2430-H2440.
72. Hercule, H. C., B. Salanova, K. Essin, H. Honeck, J. R. Falck, M. Sausbier, P. Ruth, W. H. Schunck, F. C. Luft, and M. Gollasch. 2007. The vasodilator 17,18-epoxyeicosatetraenoic acid targets the pore-forming BK alpha channel subunit in rodents. Exp. Physiol. 92: 1067-1076.
73. Ulu, A., T. R. Harris, C. Morisseau, C. Miyabe, H. Inoue, G. Schuster, H. Dong, A. M. Iosif, J. Y. Liu, R. H. Weiss, et al. 2013. Anti-infl ammatory effects of omega-3 polyunsaturated fatty acids and soluble epoxide hydrolase inhibitors in angiotensin-II-dependent hypertension. J. Cardiovasc. Pharmacol. 62: 285-297.
74. Agbor, L. N., M. T. Walsh, J. R. Boberg, and M. K. Walker. 2012. Elevated blood pressu re in cytochrome P4501A1 knockout mice is associated with reduced vasodilation to omega-3 polyunsaturated fatty acids. Toxicol. Appl. Pharmacol. 264: 351-360.
75. Chapkin, R. S., D. N. McMurray, L. A. Davidson, B. S. Patil, Y. Y. Fan, and J. R. Lupton. 2008. Bioactive dietary long-chain fatty acids: emerging mechanisms of action. Br. J. Nutr. 100: 1152-1157.
76. Jump, D. B. 2002. The biochemistry of n-3 polyunsaturated fatty acids. J. Biol. Chem. 277: 8755-8758.
77. Deckelbaum, R. J., T. S. Worgall, and T. Seo. 2006. n-3 fatty acids and gene expression. Am. J. Clin. Nutr. 83: 1520S-1525S.
78. Xiao, Y. F., D. C. Sigg, and A. Leaf. 2005. The antiarrhythmic effect of n-3 polyunsaturated fatty acids: modulation of cardiac ion channels as a potential mechanism. J. Membr. Biol. 206: 141-154.
79. Schmitz, G., and J. Ecker. 2008. The opposing effects of n-3 and n-6 fatty acids. Prog. Lipid Res. 47: 147-155.
80. Calder, P. C. 2006. n-3 polyunsaturated fatty acids, infl ammation, and infl ammatory diseases. Am. J. Clin. Nutr. 83: 1505S-1519S.
81. Shearer, G. C., and J. W. Newman. 2009. Impact of circulating esterifi ed eicosanoids and other oxylipins on endothelial function. Curr. Atheroscler. Rep. 11: 403-410.
82. Westphal, C., B. Spallek, A. Konkel, L. Marko, F. Qadri, L. M. Degraff, C. Schubert, J. A. Bradbury, V. Regitz-Zagrosek, J. R. Falck, et al. 2013. CYP2J2 o verexpression protects against arrhythmia susceptibility in cardiac hypertrophy. PLoS ONE. 8: e73490.